Author Index

ABATÁNGELO CARMEN, *see* PERDIGÓN GABRIELA.

ABEL C.A., *see* CAMPBELL PRISCILLA A.

ADLER W.H., *see* YANAGIHARA R.H.

AHLSTEDT S., *see* KRISTOFFERSON A.

ALLARDYCE R.A., *see* LINDSAY VALERIE J.

ALONSO F., SÁNCHEZ-CRESPO M. & MATO J.M. Modulatory role of cyclic AMP in the release of platelet-activating factor from human polymorphonuclear leucocytes, 493

AN T. Rapid endocytosis of soluble immune complexes by Fc receptors of normal human neutrophils, 413

ANDREW ELIZABETH & HALL J.G. IgA antibodies in the bile of rats. I. Some characteristics of the primary response, 169

ANDREW ELIZABETH & HALL J.G. IgA antibodies in the bile of rats. II. Evidence for immunological memory in secretory immunity, 177

ANDREW ELIZABETH, *see* PEPPARD JANE V.

ASHMAN R.B., *see* ASKONAS B.A.

ASKENASE P.W., BAGNALL B.G. & WORMS M.J. Cutaneous basophil-associated resistance to ectoparasites (ticks). I. Transfer with immune serum or immune cells, 501

ASKONAS B.A., MULLBACHER A. & ASHMAN R.B. Cytotoxic T-memory cells in virus infection and the specificity of helper T cells, 79

ASKONAS BRIGITTE A., *see* HACKETT C.J.

BAGNALL B.G., *see* ASKENASE P.W.

BALDWIN R.W., *see* CANTRELL D.A.

BALIGA B.S., *see* MCDERMOTT M.R.

BALTZ MARILYN L., *see* DE BEER F.C.

BARTELMEZ S.H., DODGE W.H. & BASS D.A. Antigen-mediated release of eosinophil growth stimulating factor from *Trinchinella spiralis* sensitized spleen cells: a comparison of *T. spiralis* stage-specific antigen preparations, 605

BASS D.A., *see* BARTELMEZ S.H.

BEFUS A.D., *see* MCDERMOTT M.R.

BEN-DAVID ESTER, *see* GINSBURG H.

BEN-DAVID E., *see* SHOHAM J.

BEN-EFRAIM S., *see* ZIMBER C.

BENNER R., *see* KOCH G.

BEN-SHAHAR DORIT, *see* GINSBURG H.

BERCZI I., *see* FROESE G.

BERTINI MARILENA, GALETTO G. & COMOGLIO P.M. Immune complexes and circulating antibodies against autologous leukaemic cells in patients with acute leukaemias, 569

BETTENS F., KRISTENSEN F. & DE WECK A.L. Effect of macrophages on the G_0-G_1 and G_1-S transition of thymocytes, 199

BIENENSTOCK J., *see* MCDERMOTT M.R.

BIRMINGHAM W., *see* WINCHURCH R.A.

BOBERG MERIKE, *see* VENGE P.

BOCK G., *see* RUMPOLD H.

BORASCHI DIANA, GHEZZI P., SLAMONA M. & TAGLIABUE A. IFT-β-induced reduction of superoxide anion generation by macrophages, 621

BRANDT C. JEANNE, *see* MALLEY A.

BROOKS C.G., *see* CANTRELL D.A.

BROOKS W.H., *see* ROSZMAN T.L.

BRUETON M.J., *see* LYSCOM NICOLE.

BRUTON C., *see* DE BEER F.C.

BRYANT S.M. & HILL H.R. Inability of tumour cells to elicit the respiratory burst in cytotoxic, activated macrophages, 587

BURGER M. Immunization of mouse spleen cell cultures in the absence of serum and its proteins using SiO_2 and 2-mercaptoethanol, 381

BURGER R., *see* DIERICH M.P.

BUSCHER G., *see* MUSOKE A.J.

CAMPBELL PRISCILLA A., HARTMAN A.L. & ABEL C.A. Stimulation of B cells, but not T cells or thymocytes, by a sialic acid-specific lectin, 155

CANTRELL D.A., ROBINS R.A., BROOKS C.G. & BALDWIN R.W. Phenotype of rat natural killer cells defined by monoclonal antibodies marking rat lymphocyte subsets, 97

CARAUX J., KLEIN B., THIERRY C. & SERROU B. Amplification of the polyclonal activation of human T cells. I. Null cell products promote the polyclonal proliferation of T cells, 257

CARAUX J., *see* KLEIN B.

CARTER P.B., *see* MACDONALD T.T.

CASEY M. LINETTE, HURD E.R., GILLIAM J.N., MACDONALD P.C. & JOHNSTON J.M. NAD^+-dependent 15-hydroxyprostaglandin dehydrogenase activity in kidney tissue from NZB/NZW F_1 hybrid mice, 23

CHATURVEDI U.C., GULATI LALITA & MATHUR ASHA. Inhibition of E-rosette formation and phagocytosis by human blood leucocytes after treatment with the dengue virus-induced cytotoxic factor, 679

CLAMP J.R., *see* DE BEER F.C.

COHEN N., *see* DIMARZO SHEILA J.

COMOGLIO P.M., *see* BERTINI MARILENA.

COTTRELL B.J. & STURROCK R.F. The modulation of specific and non-specific cell-mediated immunity in baboons (*Papio anubis*) infected with *Schistosoma mansoni*, 341

COULITS NELLY, *see* GECZY A.F.

CROSS R.J., *see* ROSZMAN T.L.

CYRUS MURIES, *see* SUNSHINE G.H.

CZITROM A.A., KATZ D.R. & SUNSHINE G.H. Alloreactive cytotoxic T lymphocyte responses to H-2 products on purified accessory cells, 553

DAHA M.R., *see* DOEKES G.

DE BEER F.C., BALTZ MARILYN L., MUNN E.A., FEINSTEIN A., TAYLOR J., BRUTON C., FLAMP J.R. & PEPYS M.B.

Isolation and characterization of C-reactive protein and serum amyloid P component in the rat, 55
DE WECK A.L., *see* BETTENS F.
DEPPE LINDA B., *see* MALLEY A.
DIERICH M.P., MUSSEL H.H., SCHEINER O., EHLEN T., BURGER R., PETERS H., SCHMITT M. & ZIMMER G. Differentiation of C3b receptors on human lymphocytes, phagocytes, erythrocytes and renal glomerulus cells by monoclonal antibodies, 85
DIMARZO SHEILA J. & COHEN N. An *in vivo* study of the ontogeny of alloreactivity in the frog, *Xenopus laevis*, 39
DISCIPIO R.G. The activation of the alternative pathway C3 convertase by human plasma kallikrein, 587
DOBRONYI I., *see* UHER F.
DODGE W.H., *see* BARTELMEZ S.H.
DOEKES G., VAN ES L.A. & DAHA M.R. Influence of aggregate size on the binding and activation of the first component of human complement by soluble IgG aggregates, 705
DOKMETJIAN J., *see* PERDIGÓN GABRIELA.
DRAY S., *see* GANEA DOINA.
DRUMMOND HAZEL EDITH, *see* MCINTOSH MOWAT A.

EHLEN T., *see* DIERICH M.P.
ESHHAR Z., *see* STRASSMANN G.

FARKAS A.I., MEDGYESI G.A., FÜST G., MIKLÓS KATA & GERGELEY J. Immunogenicity of antigen complexed with antibody. I. Role of different isotypes, 483
FELDMANN M., *see* KONTIAINEN S.
FERGUSON ANNE, *see* MCINTOSH MOWAT A.
FIEDEL B.A., POTEMPA L.A., FRENZKE MARIE E., SIMPSON R.M. & GEWURZ H. Platelet inhibitory effects of CRP preparations are due to a co-isolating low molecular weight factor, 15
FIEDEL B.A., SIMPSON R.M. & GEWURZ H. Activation of platelets by modified C-reactive protein, 439
FEINSTEIN A., *see* DE BEER F.C.
FITZHARRIS PENNY, *see* KNIGHT R.A.
FORSTER O., *see* RUMPOLD H.
FOSTER D.W., *see* GOETZL E.J.
FRENZKE MARIE E., *see* FIEDEL B.A.
FROESE G., BERCZI I. & ISRAELS L.G. Tumour cell–antibody interactions. II. *In vitro* studies, 313
FÜST G., *see* FARKAS A.I.

GAGNON R.F. & MACLENNAN I.C.M. Regulation of secondary antibody responses in rodents. II. The requirement for continued antigen supply to maintain IgG production, 283
GALFRÈ G. & MILSTEIN C. Chemical typing of human kappa light chain subgroups expressed by human hybrid myelomas, 125
GANEA DOINA, TEODORESCU ANA, DRAY S. & TEODORESCU M. Polyclonal B-cell activator with esterolytic activity and polyclonal gammopathy induced by allogeneic cells in rabbits, 227
GALETTO G., *see* BERTINI MARILENA.
GECZY A.F. & COULITS NELLY. Genetic control of allogeneic interactions in the guinea-pig. IV. The specific elimination of MLC suppressor cells by the *in vivo* administration of antisera against a GPLA-B region-controlled determinant, 139
GENTILE TERESA, *see* PERDIGÓN GABRIELA.
GERDES J., NAIEM M., MASON D.Y. & STEIN H. Human complement (C3b) receptors defined by a mouse monoclonal antibody, 645
GERGELY J., *see* FARKAS A.I.
GERGELY J., *see* UHER F.
GEWURZ H., *see* FIEDEL B.A.
GHEZZI P., *see* BORASCHI DIANA.
GILLIAM J.N., *see* CASEY M. LINETTE.
GINSBURG H., BEN-SHAHAR DORIT & BEN-DAVID ESTER. Mast cell growth on fibroblast monolayers: two cell entities, 371
GOETZL E.J., FOSTER D.W. & GOLDMAN D.W. Specific effects on human neutrophils of antibodies to a membrane protein constituent of neutrophil receptors for chemotactic formyl-methionyl peptides, 249
GOLDMAN D.W., *see* GOETZL E.J.
GOUBE DE LAFOREST P., *see* KLEIN B.
GRIFFITHS P., *see* YOUNG C.R.
GROESE G., BERCZI I. & ISRAELS L.G. Tumour cell–antibody interactions. I. *In vivo* experiments, 303
GULATI LALITA, *see* CHATURVEDI U.C.

HACKETT C.J. & ASKONAS BRIGITTE A. H-2 and viral haemagglutinin expression by influenza-infected cells; the proteins are close but do not cocap, 431
HÅKANSSON LENA, *see* VENGÉ P.
HALL J.G., *see* ANDREW ELIZABETH.
HARADA H., *see* KASAHARA T.
HARTMAN A.L., *see* CAMPBELL PRISCILLA A.
HED J. & STENDAHL O. Differences in the ingestion mechanisms of IgG and C3b particles in phagocytosis by neutrophils, 727
HILBERG C., *see* WINCHURCH R.A.
HILL H.R., *see* BRYANT S.M.
HURD E.R., *see* CASEY M. LINETTE.
HUSSAIN R., *see* WEISS N.

IMAI M., *see* KASAHARA T.
ISRAEL EVELYNE, *see* WAINBERG M.A.
ISRAELS L.G., *see* FROESE G.

JANSSEN A., *see* SNIPPE H.
JEFFERIS R., LOWE JENNIFER, LING N.R., PORTER P. & SENIOR STEPHANIE. Immunogenic and antigenic epitopes of immunoglobulins. I. Cross-reactivity of murine monoclonal antibodies to human IgG with the immunoglobulins of certain animal species, 71
JEGGO M.H. & WARDLEY R.C. Generation of cross-reactive cytotoxic T lymphocytes following immunization of mice with various bluetongue virus types, 629
JOHNSTON J.M., *see* CASEY M. LINETTE.

KALINER M.A., *see* LEMANSKE JR R.F.
KASAHARA T., HARADA H., SHIORI-NAKANO K., WAKASUGI H., IMAI M., MAYUMI M., SANO T. & SUGIURA A. Potentiation of natural killer cell activity of human lymphocytes *in vitro*: the participation of interferon in the stimulation with *Staphylococcus aureus* Cowan I bacteria but not with Protein A, 687
KATO K. & YAMAMOTO K. Suppression of BCG cell-wall-induced delayed-type hypersensitivity by BCG pretreatment.

II. Induction of suppressor T cells by heat-killed BCG injection, 655

KATZ D.R., *see* CZITROM A.A.

KLEEMAN JEANINE E., MASOUREDIS S.P. & VICTORIA E.J. Exposure of the $Rh_0(D)$ antigen on the surface and cytoplasmic domains of the red cell membrane, 27

KLEIN B., CARAUX J., THOMAS P. & COUBE DE LAFOREST P. Nature and mechanisms of action of co-operating cells controlling human T-colony formation, 265

KLEIN B., *see* CARAUX J.

KNIGHT R.A. & FITZHARRIS PENNY. Effects of activated T cells on natural killing, 513

KOCH G. & BENNER R. Differential requirement for B-memory and T-memory cells in adoptive antibody formation in mouse bone marrow, 697

KONTIAINEN S., TODD I. & FELDMANN M. Specific suppression of antibody responses *in vivo*. I. Effects of *in vitro* produced suppressor factor, 459

KRISTENSEN F., *see* BETTENS F.

KRISTOFFERSON A. & AHLSTEDT S. Mice do not respond with delayed hypersensitivity to pencillin-derived determinants, 537

LEA T., *see* MICHAELSEN T.E.

LEMANSKE JR R. & KALINER M.A. The experimental production of increased eosinophils in rat late-phase reactions, 561

LINDSAY VALERIE J. & ALLARDYCE R.A. The natural killer system in the rat: the relationship between natural and immune cell-mediated lysis of fibroblast targets, 423

LING N.R., *see* JEFFERIS R.

LIZZIO ELAINE F., *see* SNIPPE H.

LOMNITZER RUTH & RABSON A.R. Induction of suppressor cells after activation of human peripheral blood mononuclear cells with sodium periodate, 7

LOWE JENNIFER, *see* JEFFERIS R.

LYSCOM NICOLE & BRUETON M.J. Intraepithelial, lamina propria and Peyer's patch lymphocytes of the rat small intestine: isolation and characterization in terms of immunoglobulin markers and receptors for monoclonal antibodies, 775

MCDERMOTT M.R., MARK D.A., BEFUS A.D., BALIGA B.S., SUSKIND R.M. & BIENENSTOCK J. Impaired intestinal localization of mesenteric lymphoblasts associated with vitamin A deficiency and protein-calorie malnutrition, 1

MACDONALD P.C., *see* CASEY M. LINETTE.

MCDONALD T.L. Isolation of C1q-binding virus-antibody immune complexes from Lactic Dehydrogenase Virus (LDV)-infected mice, 365

MACDONALD T.T. & CARTER P.B. Isolation and functional characteristics of adherent phagocytic cells from mouse Peyer's patches, 769

MOWAT MCI. A., STROBEL S., DRUMMOND HAZEL EDITH & FERGUSON ANNE. Immunological responses to fed protein antigens in mice. I. Reversal of oral tolerance to ovalbumin by cyclophosphamide, 105

MACLENNAN I.C.M., *see* GAGNON R.F.

MAGNUSSON K.-E. & STJERNSTROM I. Mucosal barrier mechanism. Interplay between secretory IgA (SIgA) IgG and mucins on the surface properties and association of salmonellae with intestine and granulocytes, 239

MALLEY A., BRANDT C. JEANNE & DEPPE LINDA B. Preparation and characterization of the anti-idiotypic properties of rabbit anti-timothy antigen B helper factor and anti-mouse timothy IgE antisera, 217

MARGNI R.A., *see* PERDIGÓN GABRIELA.

MARGOLESE R.G., *see* WAINBERG M.A.

MARK D.A., *see* MCDERMOTT M.R.

MARKESBERY W.R., *see* ROSZMAN T.L.

MASAKE R.A., *see* MUSOKE A.J.

MASON D.Y., *see* GERDES J.

MASOUREDIS S.P., *see* KLEEMAN JEANINE E.

MASUDA E., TAKEMOTO T., TATSUNO T. & OBARA T. Immunosuppressive effect of a trichothecene mycotoxin, Fusarenon-X in mice, 743

MATHUR ASHA, *see* CHATURVEDI U.C.

MATO J.M., *see* ALONSO F.

MATSUMOTO T. & SHIBATA MIEKO. Activation of polyclonal antibody responses by a synthetic serum thymic factor (FTS) in CBA/N mice, 293

MAYUMI M., *see* KASAHARA T.

MEDGYESI G.A., *see* FARKAS A.I.

MERCHANT B., *see* SNIPPE H.

MICHAELSEN T. & LEA T. Sheep, rabbit and chicken antisera against a human V_H fragment: reactivity with immunoglobulins and lymphocytes, 751

MIKLÓS KATA, *see* FARKAS A.I.

MILSTEIN C., *see* GALFRÈ G.

MITA A., OHTA H. & MITA T. *In vivo* activation of mouse spleen lymphocytes by lipid A in carrier-free form, 333

MITA T., *see* MITA A.

MORRIS C.J., *see* RICHES D.W.H.

MOZES EDNA, *see* STRASSMANN G.

MULLBACHER A., *see* ASKONAS B.A.

MUNN E.A., *see* DE BEER F.C.

MUNSTER A.M., *see* WINCHURCH R.A.

MUSOKE A.J., NANTULYA V.M., BUSCHER G., MASAKE R.A. & OTIM B. Bovine immune response to *Theileria parva* neutralizing antibodies to sporozoites, 663

MUSSEL H.H., *see* DIERICH M.P.

NAIEM M., *see* GERDES J.

NAKAYAMA S., RODRIGUEZ-PINZON J., NAKAMURA S. & YOSHINAGA M. A possible role of PMN in a casein-induced enhancement of PFC response to sheep erythrocytes in mice, 669

NANTULYA V.M., *see* MUSOKE A.J.

NAUKKARINEN ANITA, *see* SYRJANEN KARI J.

OBARA T., *see* MASUDA E.

O'CONNOR G.P., *see* YOUNG C.R.

OHTA H., *see* MITA A.

OKADA H., *see* OKADA NORIKO.

OKADA NORIKO, YASUDA T., TSUMITA T. & OKADA H. Activation of the alternative complement pathway of guinea-pig by liposomes incorporated with trinitrophenylated phosphatidylethanolamine, 115

ORLANS EVA, *see* PEPPARD JANE V.

OTIM B., *see* MUSOKE A.J.

OTTESEN E.A., *see* WEISS N.

OURTH D. Neutralization of bacterial exotoxin (tetanus toxin) by channel catfish IgM antibody, 49

PARISH C.R., *see* SIA D.Y.

PAYNE A.W.R., *see* PEPPARD JANE V.
PEPPARD JANE V., ORLANS EVA, ANDREW ELIZABETH & PAYNE A.W.R. Elimination into bile of circulating antigen by endogenous IgA antibody in rats, 467
PEPYS M.B., *see* DE BEER F.C.
PETERS H., *see* DIERICH M.P.
PETERSON C., *see* VENGE P.
PLANT J.E., *see* WILSON B.M.
PORTER P., *see* JEFFERIS R.
PERIDIGÓN GABRIELA, MARGNI R.A., GENTILE TERESA, ABATÁNGELO CARMEN & DOKMETJIAN J. Human anti-tetanus toxin precipitating and co-precipitating antibodies, 183
POTEMPA L.A., *see* FIEDEL B.A.

RABSON A.R., *see* LOMNITZER RUTH.
RHODES J. & STOKES P. Interferon-induced changes in the monocyte membrane: inhibition by retinol and retinoic acid, 531
RICHES D.W.H., MORRIS C.J. & STANWORTH D.R. Studies on the possible involvement of complement component C3 in the initiation of acid hydrolase secretion by macrophages. II. Demonstration of macrophage cell surface-associated C3, and the effects of anti-C3 antibodies on lysosomal enzyme release, 473
RIEDL M., *see* RUMPOLD H.
ROBINS R.A., *see* CANTRELL D.A.
RODRIGUEZ-PINZON J., *see* NAKAYAMA S.
ROSENDAAL M., *see* WILSON B.M.
ROSZMAN T.L., CROSS R.J., BROOKS W.H. & MARKESBERY W.R. Hypothalamic–immune interactions. II. The effect of hypothalamic lesions on the ability of adherent spleen cells to limit lymphocyte blastogenesis, 737
RUMPOLD H., FORSTER O., BOCK G., SWETLY P. & RIEDL M. Antigenic heterogeneity of rat macrophages. A monoclonal antibody reacting only with alveolar but not with other types of macrophages, 637
RYLATT D.B., *see* SIA D.Y.

SABISTON B.H., *see* SHEK P.N.
SALMONA M., *see* BORASCHI DIANA.
SÁNCHEZ-CRESPO M., *see* MATO J.M.
SANDBANK U., *see* SHOHAM J.
SANO T., *see* KASAHARA T.
SCHEINER O., *see* DIERICH M.P.
SCHMITT M., *see* DIERICH M.P.
SENIOR STEPHANIE, *see* JEFFERIS R.
SERROU B., *see* CARAUX J.
SHEK P.N. & SABISTON B.H. Immune response mediated by liposome-associated protein antigen. I. Potentiation of the plaque-forming cell response, 349
SHIBATA MIEKO, *see* MATSUMOTO T.
SHIOIRI-NAKANO K., *see* KASAHARA T.
SHOHAM J., BEN-DAVID E. & SANDBANK U. Feedback inhibition of thymic secretory activity in mice treated by the thymic extract TP-1 (thymostimulin), 31
SIA D.Y., RYLATT D.B. & PARISH C.R. Anti-self receptors. V. Properties of a mouse serum factor that blocks autorosetting receptors on lymphocytes, 207
SIMPSON R.M., *see* FIEDEL B.A.
SMITH G.N. The effect of cyclosporin A on the primary immune response to allogeneic red cells in rabbits, 163
SNIPPE H., VAN HOUTE A.J., LIZZIO ELAINE F., WILLERS J.M.N. & MERCHANT B. Characterization of immunogenic properties of haptenated liposomal model membranes in mice. VI. Response in B cell-defective CBA/N mice, 545
SNIPPE H., VAN HOUTE A.J., JANSSEN A., LIZZIO ELAINE F., WILLERS J.M.N. & MERCHANT B. Characterization of immunogenic properties of haptenated liposomal model membranes in mice. VII. Synergistic responses to haptenated liposomes and haptenated thymus-dependent antigens in CBA/N mice, 613
STANWORTH D.R., *see* RICHES D.W.H.
STEIN H., *see* GERDES J.
STEJERNSTROM I., *see* MAGNUSSON K.-E.
STENDAHL O., *see* HED J.
STOKES P., *see* RHODES J.
STRASSMANN G., MOZES EDNA & ESHHAR Z. Genetic regulation of delayed-type hypersensitivity responses to poly-(Tyr,Glu)-poly(DLAla)--poly(Lys): expression of the genetic defect in the induction and manifestation phases in H-2^s and H-2^f mice, 405
STROBEL S., *see* MCINTOSH MOWAT A.
STURROCK R.F., *see* COTTRELL B.J.
SUGIURA A., *see* KASAHARA T.
SUNSHINE G.H., CYRUS MURIEL & WINCHESTER G. *In vitro* responses to the liver antigen F, 357
SUNSHINE G.H., *see* CZITROM A.A.
SUSKIND R.M., *see* MCDERMOTT M.R.
SWETLY P., *see* RUMPOLD H.
SYRJÄNEN KARI J. & NAUKKARINEN ANITA. Effects of *per anum* immunization with sheep red blood cells on the structure of the post capillary venules in the T-cell area of chicken cloacal bursa, 721

TAGLIABUE A., *see* BORASCHI DIANA.
TAKEMOTO T., *see* MASUDA E.
TATSUNO T., *see* MASUDA E.
TAYLOR J., *see* DE BEER F.C.
TEODORESCU ANA, *see* GANEA DOINA.
THIERRY C., *see* CARAUX J.
THOMAS P., *see* KLEIN B.
TODD I., *see* KONTIAINEN S.
TREPKE S., *see* DIERICH M.P.
TSUMITA T., *see* OKADA H.

UHER F., DOBRONYI I. & GERGELY J. Binding of different ligands to IgM-Fc receptors of rat leucocytes, 387

VAN BEUSEKOM H.M., VAN DE PUTTE L.B.A., VAN DEN BERG W.B. & VAN DEN BROEK W.J.M. Antigen-induced arthritis: inflammation and antigen handling after two different doses of intra-articularly injected antigen, 193
VAN DE PUTTE L.B.A., *see* VAN BEUSEKOM H.J.
VAN DEN BERG W.B., *see* VAN BEUSEKOM H.J.
VAN DEN BROEK W.J.M., *see* VAN BEUSEKOM H.J.
VAN ES L.A., *see* DOEKES G.
VAN HOUTE, A.J., *see* SNIPPE H.
VENGE P., BOBERG MERIKE, HÅKANSSON LENA & PETERSON C. Identification of a serum-derived promotor of granulocyte granule secretion. Study on a patient with chronic pruritus, 521
VICTORIA E.J., *see* KLEEMAN JEANINE E.

WAINBERG M.A., ISRAEL EVELYNE & MARGOLESE R.G.

Further studies on the mitogenic and immune-modulating effects of plasminogen activator, 715
WAKASUGI H., *see* KASAHARA T.
WARDLEY R.C., *see* JEGGO M.H.
WEISS D.W., *see* ZIMBER C.
WEISS N., HUSSAIN R. & OTTESEN E.A. IgE antibodies are more species-specific than IgG antibodies in human onchocerciasis and lymphatic filariasis, 129
WILLERS J.M.N., *see* SNIPPE H.
WILSON B.M., ROSENDAAL M. & PLANT J.E. Early haemopoietic responses to *Salmonella typhimurium* infection in resistant and susceptible mice, 395
WINCHESTER G., *see* SUNSHINE G.H.
WINCHURCH R.A., HILBERG C., BIRMINGHAM W. & MUNSTER A.M. Lipopolysaccharide-induced activation of suppressor cells: reversal by an agent which alters cyclic nucleotide metabolism, 147
WORMS M.J., *see* ASKENASE P.W.

YAMAMOTO K., *see* KATA K.
YANAGIHARA R.H. & ADLER W.H. Inhibition of mouse natural killer activity by cyclosporin A, 325
YASUDA T., *see* OKADA NORIKO.
YOSHINAGA M., *see* NAKAYAMA S.
YOUNG C.R., O'CONNOR G.P. & GRIFFITHS P. Genetic control of the antibody response to poly(LTyr, LGlu)-poly(DLAla)--poly(LLys) in mice: analysis of (low responder × low responder) F_1 hybrids, 273

ZIMBER C., BEN-EFRAIM S. & WEISS D.W. Differential inhibition of contact sensitivity by suppressor T cells and suppressor factor induced by combined treatment with dinitrobenzenesulphonate and dinitrofluorobenzene, 449
ZIMMER G., *see* DIERICH M.P.

Subject Index

Accessory cells, purified, alloreactive cytotoxic T lymphocyte responses to, 553

Acid hydrolase secretion by macrophages. II. Demonstration of macrophage cell surface-associated C3, and effects of anti-C3 antibodies on lysosomal enzyme release. Studies on possible involvement of complement component C3 in initiation of, 473

Allogeneic cells in rabbits, polyclonal B-cell activator with esterolytic activity and polyclonal gammopathy induced by, 227

Allogeneic interactions in the guinea-pig. IV. The specific elimination of MLC suppressor cells by the *in vivo* administration of antisera against a GPLA-B region-controlled determinant. Genetic control of, 139

Allogeneic red cells in rabbits, effect of cyclosporin A on primary immune response to, 163

Alloreactivity in the frog, *Xenopus laevis*, and *in vivo* study of ontogeny of, 39

Alternative complement pathway of guinea-pig by liposomes incorporated with trinitrophenylated phosphatidylethanolamine, activation of, 115

Antibodies, circulating, against autologous leukaemic cells in patients with acute leukaemias, immune complexes and, 569

Antibodies, human anti-tetanus toxin precipitating and co-precipitating, 183

Antibodies, IgA, in bile of rats. I. Some characteristics of primary response, 169

Antibodies, IgA, in bile of rats. II. Evidence for immunological memory in secretory immunity, 177

Antibodies, monoclonal, differentiation of C3b receptors on human lymphocytes, phagocytes, erythrocytes and renal glomerulus cells by, 85

Antibodies, monoclonal, marking rat lymphocyte subsets, phenotype of rat natural killer cells defined by, 97

Antibodies, murine monoclonal, to human IgG with the immunoglobulins of certain animal species, immunogenic and antigenic epitopes of immunoglobulins. I. Cross-reactivity of, 71

Antibodies, neutralizing, to sporozoites. Bovine immune response to *Theileria parva*:, 663

Antibodies to a membrane protein constituent of neutrophil receptors for chemotactic formyl-methionyl peptides, specific effects on human neutrophils of, 249

Antibody formation, adoptive, in mouse bone marrow, differential requirement for B-memory and T-memory cells, 697

Antibody interactions. I. *In vivo* experiments. Tumour cell–, 303

Antibody interactions. II. *In vitro* studies. Tumour cell–, 313

Antibody, monoclonal, reacting only with aveolar but not with other types of macrophages. Antigenic heterogeneity of rat macrophages, 637

Antibody, mouse monoclonal, human complement (C3b) receptors defined by a, 645

Antibody response to poly(LTyr, LGlu)-poly(DLAla)--poly(LLys) in mice: analysis of (low responder × low responder) F_1 hybrid, genetic control of, 273

Antibody responses, activation of polyclonal, by a synthetic serum thymic factor (FTS) in CBA/N mice, 293

Antibody responses in rodents. II. The requirement for continued antigen supply to maintain IgG production. Regulation of secondary, 283

Antibody responses *in vivo*. I. Effects of *in vitro* produced suppressor factor, specific suppression of, 459

Antigen circulating, elimination into bile by endogenous IgA antibody in rats, 467

Antigen complexed with antibody. I. Role of different isotypes. Immunogenicity of, 483

Antigen, exposure of $Rh_0(D)$, on surface of cytoplasmic domains of red cell membrane, 27

Antigen F, liver, *in vitro* responses to, 357

Antigen-induced arthritis: inflammation and antigen handling after two different doses of intra-articularly injected antigen, 193

Antigen-mediated release of eosinophil growth stimulating factor from *Trichinella spiralis* sensitized spleen cells: a comparison of *T. spiralis* stage-specific antigen preparations, 605

Antigen, liposome-associated protein, immune response mediated by. I. Potentiation of plaque-forming cell response, 349

Antigen supply to maintain IgG production. Regulation of secondary antibody responses in rodents. II. The requirement for continued, 283

Antigenic heterogeneity of rat macrophages. A monoclonal antibody reacting only with alveolar but not with other types of macrophages, 637

Antigens in mice. I. Reversal of oral tolerance to ovalbumin by cyclophosphamide. Immunological responses to fed protein, 105

Anti-idiotypic properties of rabbit anti-timothy antigen B helper factor and anti-mouse timothy IgE antisera, preparation and characterization of, 217

Antisera, sheep, rabbit and chicken, against a human V_H fragment; reactivity with immunoglobulins and lymphocytes, 751

Arthritis, antigen-induced inflammation and antigen handling after two different doses of intra-articularly injected antigen, 193

B-cell activator, polyclonal, with esterolytic activity and polyclonal gammopathy induced by allogeneic cells in rabbits, 227

B cell-defective CBA/N mice, response in, characterization of

immunogenic properties of haptenated liposomal model membrane in mice. IV, 545
B cells, stimulation of, but not T cells or thymocytes, by a sialic acid-specific lectin, 155
B-memory and T-memory cells in adoptive antibody formation in mouse bone marrow, differential requirement for, 697
Baboons (*Papio anubis*) infected with *Schistosoma mansoni*, modulation of specific and non-specific cell-mediated immunity in, 341
Basophil-associated resistance, cutaneous, to ectoparasites (ticks). I. Transfer with immune serum or immune cells, 501
BCG pretreatment. II. Induction of suppressor T cells by heat-killed BCG injection. Suppression of BCG cell-wall-induced delayed-type hypersensitivity by, 655
Bluetongue virus types, generation of cross-reactive cytotoxic T lymphocytes following immunization of mice with various, 629
Bursa, chicken cloacal, effects of *per anum* immunization with sheep red blood cells on structure of post-capillary venules in T-cell area of, 721

C3 convertase, alternative pathway, activation of, by human plasma kallikrein, 587
C3b particles in phagocytosis by neutrophils, differences in ingestion mechanisms of IgG and, 727
C3b receptors on human lymphocytes, phagocytes, erythrocytes and renal glomerulus cells by monoclonal antibodies, differentiation of, 85
C-reactive protein, modified, activation of platelets by, 439
C-reactive protein and serum amyloid P component in the rat, isolation and characterization of, 85
Casein-induced enhancement of PFC response to sheep erythrocytes in mice, possible role of PMN in a, 669
CBA/N mice, activation of polyclonal antibody responses by a synthetic serum thymic factor (FTS) in, 293
Cell-mediated immunity in baboons (*Papio anubis*) infected with *Schistosoma mansoni*, modulation of specific and non-specific, 341
Cell-mediated lysis, natural and immune, of fibroblast targets, natural killer system in the rat: relationship between, 423
C1q-binding virus-antibody immune complexes from Lactic Dehydrogenase Virus (LDV)-infected mice, 365
Complement, alternative pathway, activation of, of guinea-pig by liposomes incorporated with trinitrophenylated phosphatidylethanolamine, 115
Complement (C3b) receptors, human, defined by a mouse monoclonal antibody, 645
Complement component C3 in initiation of acid hydrolase secretion by macrophages. II. Demonstration of macrophage cell surface-associated C3 and effects of anti-C3 antibodies on lysosomal enzyme release. Studies on possible involvement of, 473
Complement, first component of human, influence of aggregate size on binding and activation of, by soluble IgG aggregates, 705
Contact sensitivity, differential inhibition of, by suppressor T cells and suppressor factor induced by combined treatment with dinitrobenzenesulphonate and dinitrofluorobenzene, 449
CRP preparations, platelet inhibitory effects of, are due to a co-isolating low molecular weight factor, 15
Cyclic AMP, modulatory role of, in release of platelet-activating factor from human polymorphonuclear leucocytes, 493
Cyclosporin A, effect of, on primary immune response to allogeneic red cells in rabbits, 163
Cyclosporin A, inhibition of mouse natural killer activity by, 325
Cytotoxic factor, dengue virus-induced, inhibition of E-rosette formation and phagocytosis by human blood leucocytes after treatment with, 679
Cytotoxic T-memory cells in virus infection and the specificity of helper T cells, 79

Delayed hypersensitivity to penicillin-derived determinants, mice do not respond with, 537
Delayed-type hypersensitivity, BCG cell wall-induced, suppression of, by BCG pretreatment. II. Induction of suppressor T cells by heat-killed BCG injection, 655
Delayed-type hypersensitivity responses to poly(Tyr, Glu)-poly(DLAla)--poly(Lys): expression of the genetic defect in the induction and manifestation phases in H-2^s and H-2^f mice, genetic regulation of, 405
Dengue virus-induced cytotoxic factor, inhibition of E-rosette formation and phagocytosis by human blood leucocytes after treatment with, 679

E-rosette formation and phagocytosis by human blood leucocytes after treatment with dengue virus-induced cytotoxic factor, inhibition of, 679
Ectoparasites (ticks), cutaneous basophil-associated resistance to, transfer with immune serum or immune cells. I, 501
Endocytosis, rapid, of soluble immune complexes by Fc receptors of normal human neutrophils, 413
Eosinophil growth stimulating factor, antigen-mediated release of, from *Trichinella spiralis* sensitized spleen cells: a comparison of *T. spiralis* stage-specific antigen preparations, 605
Eosinophils in rat late-phase reactions, experimental production of increased, 561
Epitopes, immunogenic and antigenic, of immunoglobulins. I. Cross-reactivity of murine monoclonal antibodies to human IgG with the immunoglobulins of certain animal species, 71
Erythrocytes and renal glomerulus cells by monoclonal antibodies, differentiation of C3b receptors on human lymphocytes, phagocytes, 85
Erythrocytes, sheep, in mice, possible role of PMN in a casein-induced enhancement of PFC response to, 669
Esterolytic activity and polyclonal gammopathy induced by allogeneic cells in rabbits, polyclonal B-cell activator with, 227
Exotoxin (tetanus toxin), neutralization of bacterial, by channel catfish IgM antibody, 49

Fc receptors of normal human neutrophils, rapid endocytosis of soluble immune complexes, 413
Fibroblast monolayers, mast cell growth on: two-cell entities, 371
Fibroblast targets, natural killer system in the rat: relation-

ship between natural and immune cell-mediated lysis of fibroblast targets, 423
Fusarenon-X in mice, immunosuppressive effect of a trichothecene mycotoxin, 743

G_0-G_1 and G_1-S transition of thymocytes, effect of macrophages on, 199
Genetic control of antibody response to poly(LTyr, LGlu)-poly(DLAla)--poly(LLys) in mice: analysis of (low responder × low responder) F_1 hybrids, 273
Glomerulus cells, renal, differentiation of C3b receptors on human lymphocytes, phagocytes, erythrocytes and, by monoclonal antibodies, 85
GPLA-B region-controlled determinant, specific elimination of MLC suppressor cells by the *in vivo* administration of antisera against. Genetic control of allogeneic interactions in the guinea-pig. IV, 139
Granulocyte granule secretion: study on a patient with chronic pruritus. Identification of serum-derived promoter of, 521

H-2 products on purified accessory cells, alloreactive cytotoxic T lymphocyte responses to, 553
*H-2 and viral haemagglutinin expression by influenza-*infected cells; the proteins are close but do not cocap, 431
H-2^s and H-2^f mice, expression of the genetic defect in the induction and manifestation phases in genetic regulation of delayed-type hypersensitivity responses to poly(Tyr, Glu)-poly(DLAla)--poly(Lys), 405
Haemagglutinin, viral, H-2 and expression by influenza-infected cells; the proteins are close but do not cocap, 431
Haemopoietic responses, early, to Salmonella typhimurium infection in resistant and susceptible mice, 395
Haptenated liposomal model membranes in mice. VI. Response in B cell-defective CBA/N mice. Characterization of immunogenic properties of, 545
Haptenated liposomes and haptenated thymus-dependent antigens in CBA/N mice. Characterization of immunogenic properties of haptenated liposomal model membranes in mice. *VII. Synergistic response to, 613*
15-hydroxyprostaglandin dehydrogenase activity in kidney tissue from NZB/NZW F_1 hybrid mice, NAD^+-dependent, 23
Hypothalamic–immune interactions. II. The effect of *hypothalamic lesions on the ability of adherent spleen cells* to limit lymphocyte blastogenesis, 737

IFN-β-induced reduction of superoxide anion generation by macrophages, 621
IgA antibodies in bile of rats. I. Some characteristics of primary response, 169
IgA antibodies in bile of rats. II. Evidence for immunological memory in secretory immunity, *177*
IgA antibody, endogenous, in rats, elimination into bile of circulating antigen by, 467
IgA, secretory (SIgA), IgG and mucins on the surface properties and association of salmonellae with intestine *and granulocytes. Mucosal barrier mechanisms. Interplay* between, 239
IgE antibodies are more species-specific than IgG antibodies in human onchocerciasis and lymphatic filariasis, *129*
IgG aggregates, soluble, influence of aggregate size on binding and activation of first component of human complement by, 705
IgG antibodies in human onchocerciasis and lymphatic filariasis, IgE antibodies are more species-specific than, 129
IgG and C3b particles in phagocytosis by neutrophils, differences in ingestion mechanisms of, 727
IgG, human, cross-reactivity of murine monoclonal antibodies to, with the immunoglobulins of certain animal species. Immunogenic and antigenic epitopes of immunoglobulins. I, 71
IgG and mucins on the surface properties and association of salmonellae with intestine and granulocytes. Mucosal barrier mechanisms. Interplay between secretory IgA (SIgA), 239
IgG production, requirement for continued antigen supply to maintain. Regulation of secondary antibody responses in rodents. II, 283
IgM antibody, neutralization of bacterial exotoxin (tetanus toxin) by channel catfish, 49
IgM-Fc receptors of rat leucocytes, binding of different ligands to, 387
Immune complexes and circulating antibodies against autologous leukaemic cells in patients with acute leukaemias, 569
Immune complexes, isolation of C1q-binding virus-antibody, from Lactic Dehydrogenase Virus (LDV)-infected mice, 365
Immune complexes, soluble, rapid endocytosis of, by Fc receptors of normal human neutrophils, 413
Immune-modulating effects of plasminogen activator, further studies on mitogenic and, 715
Immune response, bovine, to Theileria parva: neutralizing antibodies to sporozoites, 663
Immune response mediated by liposome-associated protein antigen. I. Potentiation of plaque-forming cell response, 349
Immune response, primary, to allogeneic red cells in rabbits, effect of cyclosporin A on, 163
Immunogenicity of antigen complexed with antibody. I. Role of different isotypes, *483*
Immunoglobulin markers and receptors for monoclonal antibodies, intraepithelial, lamina propria and Peyer's patch lymphocytes of rat small intestine: isolation and characterization in terms of, 775
Immunoglobulins. I. Cross-reactivity of murine monoclonal antibodies to human IgG with the immunoglobulins of certain animal species, immunogenic and antigenic epitopes of, *71*
Immunoglobulins and lymphocytes, sheep, rabbit and chicken antisera against a human V_H fragment: reactivity with, 751
Immunological memory in secretory immunity, IgA antibodies *in bile of rats. II. Evidence for, 177*
Immunosuppressive effect of a trichothecene mycotoxin, Fusarenon-A in mice, 743
Influenza-infected cells, H-2 and viral haemagglutinin expression by; the proteins are close but do not cocap, 431
*Ingestion mechanisms of IgG and C3b particles in phago*cytosis by neutrophils, differences in, 727
Inhibition, differential, of contact sensitivity by suppressor T cells and suppressor factor induced by combined treatment

with dinitrobenzene sulphonate and dinitrofluorobenzene, 449

Interferon-induced changes in the monocyte membrane: *inhibition by retinol and retinoic acid*, 531

Interferon in stimulation with *Staphylococcus aureus* Cowan I bacteria but not with Protein A. Potentiation of natural killer cell activity of human lymphocytes *in vitro*: participation of, 687

Intraepithelial, lamina propria and Peyer's patch lymphocytes of rat small intestine: isolation and characterization in terms of immunoglobulin markers and receptors for monoclonal antibodies, 775

Kallikrein, human plasma, activation of alternative pathway C3 convertase by, 587

Kappa light chain, human, subgroups expressed by human hybrid myelomas, chemical typing of, 125

Lactic Dehydrogenase Virus (LDV)-infected mice, isolation of C1q-binding virus-antibody immune complexes from, 365

Lamina propria, intraepithelial, and Peyer's patch lymphocytes of rat small intestine: isolation and characterization *in terms of immunoglobulin* markers and receptors for monoclonal antibodies, 775

Lectin, sialic acid-specific, stimulation of B cells, but not T cells or thymocytes, by a, 155

Leucocytes, human blood, inhibition of E-rosette formation and phagocytosis by, after treatment with dengue virus-induced cytotoxic factor, 679

Leucocytes, rat, binding of different ligands to IgM-Fc *receptors of*, 387

Leukaemic cells, autologous, in patients with acute leukaemias, immune complexes and circulating antibodies against, 569

Lipid A in carrier-free form, *in vivo* activation of mouse *spleen lymphocytes by*, 333

Lipopolysaccharide-induced activation of suppressor cell: reversal by an agent which alters cyclic nucleotide metabolism, 147

Liposomal model membranes, haptenated, in mice. VI. Response in B cell-defective CBA/N mice. Characterization of immunogenic properties of, 545

Liposomal model membranes in mice. VII. Synergistic *responses to haptenated liposomes and haptenated* thymus-dependent antigens in CBA/N mice. Characterization of immunogenic properties of hapenated, 613

Liposome-associated protein antigen, I. Potentiation of plaque-forming cell response. Immune response mediated by, 349

Liposomes incorporated with trinitrophenylated phosphatidylethanolamine, activation of alternative complement *pathway of guinea-pig by*, 115

Low molecular weight factor, co-isolating platelet inhibitory effects of CRP preparations are due to a, 15

Lymphatic filariasis, IgE antibodies are more species-specific than IgG antibodies in human onchocerciasis and, 129

Lymphocyte blastogenesis, effect of hypothalamic lesions on ability of adherent spleen cells to limit, hypothalamic–immune interactions. II, 737

Lymphocytes, sheep, rabbit and chicken antisera against a human V_H fragment: reactivity with immunoglobulins and, 751

Lymphocyte subsets, rat, phenotype of rat natural killer cells defined by monoclonal antibodies marking, 97

Lymphoblasts, mesenteric, associated with vitamin A deficiency and protein-calorie malnutrition, impaired intestinal localization of, 1

Lymphocytes, human, differentiation of C3b receptors on, phagocytes, erythrocytes and renal glomerulum cells by monoclonal antibodies, 85

Lymphocytes, human, potentiation of natural killer cell activity of: participation of interferon in stimulation with *Staphylococcus aureus* Cowan I bacteria but not with *Protein A*, 687

Lymphocytes, intraepithelial, lamina propria and Peyer's patch, of rat small intestine: isolation and characterization in terms of immunoglobulin markers and receptors for monoclonal antibodies, 775

Lymphocytes, *mouse spleen, in vivo activation of, by lipid A* in carrier-free form, 333

Lysosomal enzyme release, demonstration of macrophage *cell surface-associated C3*, and effects of anti-C3 antibodies on. Studies on possible involvement of complement component C3 in initiation of acid hydrolase secretion by macrophages. II, 473

Macrophages, cytotoxic, activated, inability of tumour cells to elicit respiratory burst in, 587

Macrophages on G_0-G_1 and G_1-S transition of thymocytes, effect of, 199

Macrophages, IFN-β-induced reduction of superoxide anion generation by, 621

Macrophages, rat, antigenic heterogeneity of. A monoclonal antibody *reacting only with alveolar but not with other* types of macrophages, 637

Macrophages, studies on possible involvement of complement component C3 in initiation of acid hydrolase secretion by. II. Demonstration of macrophage cell surface-associated C3, and effects of anti-C3 antibodies on lysosomal enzyme release, 473

Membrane protein constituent of neutrophil receptors for *chemotactic formyl-methionyl peptides, specific effects on* human neutrophils of antibodies to a, 249

Mast cell growth on fibroblast monolayers: two-cell entities, 371

2-mercaptoethanol, immunization of mouse spleen cell cultures in absence of serum and its proteins using SiO_2 and, 381

Mesenteric lymphoblasts associated with vitamin A deficiency and protein-calorie malnutrition, impaired intestinal localization of, 1

Mitogenic and immune-modulating effects of plasminogen activator, further studies on, 715

MLC suppressor cells, specific elimination of, by the *in vivo administration of antisera against a GPLA-B* region-controlled determinant. Genetic control of alloegneic interactions in the guinea-pig. IV, 139

Monoclonal antibodies, immunoglobulin markers and receptors for, intraepithelial, lamina propria and Peyer's patch lymphocytes of rat small intestine: isolation and characterization in terms of, 775

Monoclonal antibodies marking rat lymphocyte subsets, phenotype of rat natural killer cells defined by, 97
Monocyte membrane: inhibition by retinol and retinoic acid. Interferon-induced changes in, 531
Mononuclear cells with sodium periodate, induction of *suppressor cells after activation of human peripheral* blood, 7
Mucosal barrier mechanism. Interplay between secretory IgA (SIgA), IgG and mucins on the surface properties and association of salmonellae with intestine and granulocytes, 239
Mycotoxin, trichothecene, immunosuppressive effect of a, Fusarenon-X in mice, 743
Myelomas, human hybrid, chemical typing of human kappa light chain subgroups expressed by, 125

NAD^+-dependent 15-hydroxyprostaglandin dehydrogenase activity in kidney tissue from NZB/NZW F_1 hybrid mice, 23
Natural killer activity, mouse by cyclosporin A, inhibition of, 325
Natural killer cell activity of human lymphocytes *in vitro*: the participation of interferon in stimulation with *Staphylococcus aureus* Cowan I bacteria but not with Protein A. Potentiation of, 687
Natural killer cells, rat, defined by monoclonal antibodies marking rat lymphocyte subsets, 97
Natural killer system in the rat: relationship between natural and immune cell-mediated lysis of fibroblast targets, 423
Natural killing, effects of activated T cells on, 513
Neutrophils, differences in ingestion mechanisms of IgG and *C3b particles in phagocytosis by*, 727
Neutrophils, normal human, rapid endocytosis of soluble immune complexes by Fc receptors of, 413
Neutrophils, specific effects on human, of antibodies to a membrane protein constituent of neutrophil receptors for chemotactic formyl-methionyl peptides, 249
Nucleotide metabolism, cyclic, lipopolysaccharide-induced activation of suppressor cell, 147
Null cell products promote the polyclonal proliferation of T cells. Amplification of polyclonal activation of human T cells. I, 257

Onchocerciasis and lymphatic filariasis, human, IgE antibodies are more species-specific than *IgG antibodies in*, 129
Ontogeny of alloreactivity in the frog, *Xenopus leavis*, an *in vivo* study of, 39
Oral tolerance to ovalbumin, immunological responses to fed *protein antigens in mice. I. Reversal of, by cyclophospha*mide, 105

Penicillin-derived determinants, mice do not respond with delayed hypersensitivity to, 537
Peptides, chemotactic formyl-methionyl, specific effects on human neutrophils of antibodies to a membrane protein constituent of neutrophil receptors for, 249
Peripheral blood mononuclear cells, human, with sodium periodate, induction of suppressor cells after activation of, 7
Peyer's patch lymphocytes, intraepithelial, lamina propria and, of rat small intestine: isolation and characterization in terms of immunoglobulin markers and receptors for monoclonal antibodies, 775
Peyer's patches, mouse, isolation and functional characteristics of adherent phagocytic cells from, 769
PFC response to sheep erythrocytes in mice, possible role of PMN in a casein-induced enhancement of, 669
Phagocytes, erythrocytes and renal glomerulus cells, differentiation of C3b receptors on human lymphocytes by monoclonal antibodies, 85
Phagocytic cells, adherent, isolation and functional characteristics of, from mouse Peyer's patches, 769
Phagocytosis by human blood leucocytes after treatment with dengue virus-induced cytotoxic factor, inhibition of E-rosette formation and, 679
Phenotype of rat natural killer cell defined by monoclonal antibodies marking rat lymphocyte subsets, 97
Plaque-forming cell response, potentiation of. Immune response mediated by liposome-associated protein antigen. I, 349
Plasminogen activator, further studies on mitogenic and immune-modulating effects of, 715
Platelet-activating factor, release of, from human polymorphonuclear leucocytes, modulatory role of cyclic AMP in, 493
Platelets, activation of, by modified C-reactive protein, 439
Platelet inhibitory effects of CRP preparations are due to a co-isolating low molecular weight factor, 15
PMN, possible role of, in a casein-induced enhancement of PFC response to sheep erythrocytes in mice, 669
Polyclonal activation of human T cells. I. Null cell products promote polyclonal proliferation of T cells. Amplification of, 257
Polyclonal antibody responses, activation of, by a synthetic serum thymic factor (FTS) in CBA/N mice, 293
Polyclonal gammopathy induced by allogeneic cells in rabbits, polyclonal B-cell activator with esterolytic activity and, 227
Poly(LTyr, LGlu)-poly(DLAla)--poly(LLys) in mice: analysis of (low responder × low responder) F_1 hybrid, genetic control of antibody response to, 273
Polymorphonuclear leucocytes, human, modulatory role of *cyclic AMP in release of platelet-activating factor from*, 493
Poly(Tyr,Glu)-poly(DLAla)--poly(Lys): expression of the genetic defect in the induction and manifestation phases in $H\text{-}2^s$ and $H\text{-}2^r$ mice, genetic regulation of delayed-type hypersensitivity responses to, 405
Protein A, potentiation of natural killer cell activity of human lymphocytes *in vitro*: participation of interferon in stimulation with *Staphylococcus aureus* Cowan I bacteria but not with Protein A, 687
Protein antigens in mice. I. Reversal of oral tolerance to ovalbumin by cyclophosphamide. Immunological responses to fed, 105
Protein-calorie malnutrition, impaired intestinal localization of mesenteric lymphoblasts associated with vitamin A deficiency and, 1
Protein, modified C-reactive, activation of platelets by, 439
Pruritus, chronic, study on a patient with. Identification of serum-derived promoter of granulocyte granule secretion, 521

Rat late-phase reactions, experimental production of increased eosinophils in, 561
Receptors, anti-self. V. Properties of a mouse serum factor that blocks autorosetting receptors on lymphocytes, 207
Respiratory burst in cytotoxic, activated macrophages, inability of tumour cells to elicit, 587
Retinol and retinoic acid, inhibition by, interferon-induced changes in monocyte membrane, 531
Rh_o(D) antigen on surface and cytoplasmic domains of red cell membrane, exposure of, 27

Salmonella typhimurium infection in resistant and susceptible mice, early haemopoietic responses to, 395
Salmonellae with intestine and granulocytes. Mucosal barrier mechanisms. Interplay between secretory IgA (SIgA), IgG and mucins on the surface properties and association, 239
Schistosoma mansoni, modulation of specific and non-specific cell-mediated immunity in baboons (*Papio anubis*) infected with, 341
Secretory IgA (SIgA), IgG and mucins on the surface properties and association of salmonellae with intestine and granulocytes. Mucosal barrier mechanism, 239
Secretory immunity. IgA antibodies in bile of rats. II. Evidence for immunological memory in, 177
Serum amyloid P component in the rat, isolation and characterization of C-reactive protein and, 85
Serum-derived promoter of granulocyte granule secretion: study of a patient with chronic pruritus. Identification of, 521
Serum factor, mouse, that blocks autorosetting receptors on lymphocytes. Anti-self receptors. V. Properties of a, 207
Sheep red blood cells, effects of *per anum* immunization with, on structure of post-capillary venules in T-cell area of chicken cloacal bursa, 721
SiO_2 and 2-mercaptoethanol, immunization of mouse spleen cell cultures in absence of serum and its proteins using, 381
Sodium periodate, induction of suppressor cells after activation of human peripheral blood mononuclear cells, 7
Spleen cell cultures, mouse, immunization of, in absence of serum and its proteins using SiO_2 and 2-mercaptoethanol, 381
Spleen cells, adherent, effect of hypothalamic lesions on ability of, to limit lymphocyte blastogenesis, hypothalamic–immune interactions. II, 737
Spleen cells, *Trichinella spiralis* sensitized: a comparison of *T. spiralis* stage-specific antigen preparations, antigen-mediated release of eosinophil growth stimulating factor from, 605
Staphylococcus aureus Cowan I bacteria, participation of interferon in stimulation with, but not with Protein A. Potentiation of natural killer cell activity of human lymphocytes *in vitro*, 687
Superoxide anion generation by macrophages, IFN-β-induced reduction of, 621
Suppression of BCG cell-wall-induced delayed-type hypersensitivity by BCG pretreatment. II. Induction of suppressor T cells by heat-killed BCG injection, 655
Suppression, specific, of antibody responses *in vivo*. I. Effects of *in vitro* produced suppressor factor, 459
Suppressor cell, lipopolysaccharide-induced activation of: reversal by an agent which alters cyclic nucleotide metabolism, 147
Suppressor cells, induction of, after activation of human peripheral blood mononuclear cells with sodium periodate, 7
Suppressor cells, specific elimination of MLC, by the *in vivo* administration of antisera against a GPLA-B region-controlled determinant. Genetic control of allogeneic interactions in the guinea-pig. IV, 139
Suppressor T cells and suppressor factor, differential inhibition of contact sensitivity by, induced by combined treatment with dinitrobenzenesulphonate and dinitrofluorobenzene, 449
Suppressor factor induced by combined treatment with dinitrobenzenesulphonate and dinitrofluorobenzene, differential inhibition of contact sensitivity by suppressor T cells and, 449
Synergistic responses to haptenated liposomes and haptenated thymus-dependent antigens in CBA/N mice. Characterization of immunogenic properties of haptenated liposomal model membranes in mice. VII, 613

T-cell area of chicken cloacal bursa, effects of *per anum* immunization with sheep red blood cells on post-capillary venules in, 721
T cells, activated, effects of, on natural killing, 513
T cells, human. I. Null cell products promote polyclonal proliferation of T cells. Amplification of polyclonal activation of, 257
T cells, induction of suppressor, by heat-killed BCG injection. Suppression of BCG cell-wall-induced delayed-type hypersensitivity by BCG pretreatment. II, 655
T cells, stimulation of B cells, but not, of thymocytes, by a sialic acid-specific lectin, 155
T cells, suppressor, and suppressor differential inhibition of contact sensitivity by, induced by combined treatment with dinitrobenzenesulphonate and dinitrofluorobenzene, 449
T-colony formation, human, nature and mechanisms of action of co-operating cells controlling, 265
T lymphocyte responses, alloreactive cytotoxic, to H-2 products on purified accessory cells, 553
T lymphocytes, cross-reactive cytotoxic, generation of, following immunization of mice with various bluetongue virus types, 629
T-memory cells in adoptive antibody formation in mouse bone marrow, differential requirement for B-memory and, 697
T-memory cells, cytotoxic, in virus infection and the specificity of helper T cells, 79
(Tetanus toxin), neutralization of bacterial exotoxin, by Channel catfish IgM antibody, 49
Theileria parva: neutralizing antibodies to sporozoites. Bovine immune response to, 663
Thymic factor (FTS), synthetic serum, in CBA/N mice, activation of polyclonal antibody responses by a, 293
Thymic secretory activity in mice treated by thymic extract TP-1 (thymostimulin), feedback inhibition of, 31
Thymocytes, G_0-G_1 and G_1-S transition of, effect of macrophages on, 199
Thymocytes, stimulation of B cells, but not T cells or, by a sialic acid-specific lectin, 155
Thymus-dependent antigens, haptenated, in CBA/N mice. Characterization of immunogenic properties of hap-

tenated liposomal model membranes in mice. VII. Synergistic responses to haptenated liposomes and, 613
Timothy antigen B helper factor, rabbit anti-, and anti-mouse timothy IgE antisera, preparation and characterization of anti-idiotypic properties of, 217
Timothy IgE antisera, anti-mouse preparation and characterization of anti-idiotypic properties of rabbit anti-timothy antigen B helper factor and, 217
Trichinella spiralis sensitized spleen cells: a comparison of *T. spiralis* stage-specific antigen preparations, antigen-mediated release of eosinophil growth stimulating factor from, 605
Trinitrophenylated phosphatidylethanolamine, activation of alternative complement pathway of guinea-pig by liposomes incorporated with, 115
Tumour cell–antibody interactions. I. *In vivo* experiments, 303
Tumour cell–antibody interactions. II. *In vitro* studies, 313
Tumour cells, inability of, to elicit respiratory burst in cytotoxic, activated macrophages, 587

Venules, post capillary, in T-cell area of chicken cloacal bursa, effects of *per anum* immunization with sheep red blood cells on structure of, 721
Vitamin A deficiency and protein-calorie malnutrition, impaired intestinal localization of mesenteric lymphoblasts associated with, 1

Xenopus laevis, an *in vivo* study of ontogeny of alloreactivity in the frog, 39